Mintz represented biotechnology company Viela Bio, Inc. in its initial public offering of 7.9 million shares of its common stock, which was priced at $19 per share. On October 3, Viela Bio began trading on the Nasdaq Global Select Market under the symbol “VIE.” The offering is expected to close on October 7, 2019, subject to customary closing conditions.

Headquartered in Gaithersburg, Maryland, Viela Bio is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases. View the company’s full press release here.

The Mintz team was led by Members Christopher E. Jeffers and John T. Rudy, and Member and Chair of the Securities & Capital Markets Practice and Co-Chair of the Life Sciences Practice Jonathan L. Kravetz.